HealthEquity (HQY) Competitors

HealthEquity (NASDAQ:HQY) and CDK Global (NASDAQ:CDK) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk, earnings and community ranking.

Which has preferable valuation and earnings, HQY or CDK?

CDK Global has higher revenue and earnings than HealthEquity. CDK Global is trading at a lower price-to-earnings ratio than HealthEquity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HealthEquity	$999.59M	7.11	$55.71M	$0.64	127.63
CDK Global	$1.67B	3.82	$1.03B	$2.09	26.20

Which has more risk & volatility, HQY or CDK?

HealthEquity has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500. Comparatively, CDK Global has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500.

Does the media refer more to HQY or CDK?

In the previous week, HealthEquity had 5 more articles in the media than CDK Global. MarketBeat recorded 7 mentions for HealthEquity and 2 mentions for CDK Global. HealthEquity's average media sentiment score of 1.15 beat CDK Global's score of 0.08 indicating that HealthEquity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HealthEquity	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CDK Global	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do insiders and institutionals hold more shares of HQY or CDK?

99.6% of HealthEquity shares are owned by institutional investors. Comparatively, 92.9% of CDK Global shares are owned by institutional investors. 2.2% of HealthEquity shares are owned by insiders. Comparatively, 0.5% of CDK Global shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Do analysts recommend HQY or CDK?

HealthEquity currently has a consensus price target of $96.17, indicating a potential upside of 17.74%. Given HealthEquity's higher probable upside, equities analysts clearly believe HealthEquity is more favorable than CDK Global.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HealthEquity	0 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	3.00
CDK Global	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Is HQY or CDK more profitable?

CDK Global has a net margin of 14.28% compared to HealthEquity's net margin of 5.57%. CDK Global's return on equity of 67.84% beat HealthEquity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HealthEquity	5.57%	6.91%	4.41%
CDK Global	14.28%	67.84%	11.15%

Does the MarketBeat Community prefer HQY or CDK?

HealthEquity received 148 more outperform votes than CDK Global when rated by MarketBeat users. Likewise, 69.24% of users gave HealthEquity an outperform vote while only 56.11% of users gave CDK Global an outperform vote.

Company	Underperform	Outperform
HealthEquity	Outperform Votes 511 69.24%	Underperform Votes 227 30.76%
CDK Global	Outperform Votes 363 56.11%	Underperform Votes 284 43.89%

Summary

HealthEquity beats CDK Global on 10 of the 17 factors compared between the two stocks.